A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Stan ogólny pacjenta pozwalający na aktywność w ciągu dnia (skala 0-2)
- •Stosowanie antykoncepcji podczas leczenia i przez najmniej 90 dni po ostatniej dawce
- •Dla przewlekłej białaczki limfocytowej: konieczność leczenia według międzynarodowych kryteriów
- •Obecność mierzalnego guza do oceny odpowiedzi na leczenie
- •Liczba limfocytów poniżej 25000 komórek/mikroliter
- •Co najmniej jedna wcześniejsza linia leczenia chemioterapią
- •Dla chłoniaka rozlanego z dużych komórek B: wiek poniżej 80 lat
- •Prawidłowa funkcja serca (wyrzutność lewej komory minimum 50%)
✗ Disqualifies
- •Chłoniak ośrodkowego układu nerwowego
- •Zabieg chirurgiczny w ciągu 14 dni przed rozpoczęciem leku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (64)
Research Site
Boston, United States
Research Site
Hackensack, United States
Research Site
New Brunswick, United States
Research Site
New York, United States
Research Site
New York, United States
Research Site
Charlotte, United States
Research Site
Charlotte, United States
Research Site
Columbus, United States
Research Site
Portland, United States
Research Site
Philadelphia, United States
Research Site
Pittsburgh, United States
Research Site
Providence, United States
Research Site
Houston, United States
Research Site
Heidelberg, Australia
Research Site
Melbourne, Australia
Research Site
Nedlands, Australia
Research Site
Beijing, China
Research Site
Guangzhou, China
Research Site
Jinan, China
Research Site
Tianjin, China
Research Site
Zhengzhou, China
Research Site
Ostrava - Poruba, Czechia
Research Site
Prague, Czechia
Research Site
Praha 2 - Nové Město, Czechia
Research Site
Aalborg, Denmark
Research Site
Aarhus N, Denmark
Research Site
Copenhagen, Denmark
Research Site
Odense C, Denmark
Research Site
Clermont-Ferrand, France
Research Site
Montpellier, France
Research Site
Paris, France
Research Site
Saint-Cloud, France
Research Site
Villejuif, France
Research Site
Cologne, Germany
Research Site
Homburg, Germany
Research Site
Kiel, Germany
Research Site
Mainz, Germany
Research Site
München, Germany
Research Site
Würzburg, Germany
Research Site
Bologna, Italy
Research Site
Milan, Italy
Research Site
Kōtoku, Japan
Research Site
Matsuyama, Japan
Research Site
Nagoya, Japan
Research Site
Busan, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Palma de Mallorca, Spain
Research Site
Santiago de Compostela, Spain
Research Site
Valencia, Spain
Research Site
Changhua, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Derriford, United Kingdom
Research Site
London, United Kingdom
Research Site
Oxford, United Kingdom
Research Site
Southampton, United Kingdom
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.